The current clinical knowledge on the treatment of gambling disorder: A summary

Karel Hloch, Přemysl Mladěnka, Martin Doseděl, Walter Adriani, Francesca Zoratto

Research output: Contribution to journalReview articlepeer-review


Gambling disorder (GD) is a topical problem in developed countries and may be present in 1–3% of the general population. The pathophysiology of this disorder is largely unknown but it shares similarities to other behavioral addictions. Multiple neurotransmitter systems, including dopaminergic, serotonergic, noradrenergic, glutamatergic, and opioidergic, have been implicated in GD. Based on available articles, only the opioid antagonist naltrexone has been documented to demonstrate clinical efficacy in multiple studies including double-blind studies. Nalmefene, another opioid antagonist, may be active as well but its dose-response effect remains unclear. Contrarily, current test results do not support the therapeutic use of any antidepressant drug. Some positive data has been made available supporting the use of N-acetylcystein, but more studies are needed to confirm this. No clear or definite information is currently available for other drugs.

Original languageEnglish
Article numbere21976
Issue number8
Publication statusPublished - Aug 1 2017


  • addictive behavior
  • drug therapy
  • gambling disorder
  • pharmacological treatment

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience


Dive into the research topics of 'The current clinical knowledge on the treatment of gambling disorder: A summary'. Together they form a unique fingerprint.

Cite this